Successful testing protocols in virology.
Early Disease Detection
MOLECULAR TESTING TO GUIDE PREEMPTIVE THERAPY FOR CMV INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS
CMV is a member of the herpesviridae family of viruses. Infection is common, with 40-100% of adults being seropositive. The two periods of increased infection occur in the perinatal period and during the reproductive years (1). After primary infection, CMV will establish a life-long latent infection. Reactivation of infection can occur in immunocompromised individuals, and for this reason, CMV infection is a major infectious complication in solid organ transplant recipients (2). The clinical presentation of CMV infection in these patients includes febrile syndromes, retinitis, pneumonitis, esophagitis, and colitis (2). In addition to reactivation of latent infection, primary CMV infection may occur in solid organ transplant recipients. Primary infections that occur when patients are immunosuppressed tend to be more severe than reactivation of latent infections.
A key diagnostic issue for CMV infection is distinguishing active disease from latent infection. The goals are to identify patients at risk for disease and to give preemptive therapy to prevent the development of CMV disease. This approach to using preemptive therapy relies on the availability of a test that can predict the risk of developing CMV disease. Quantitative molecular assays have been developed to determine whether CMV viral load concentrations are useful in differentiating latent infection from active disease. Two such assays are the hybrid capture assay (Digene Corp.) and Amplicor CMV Monitor Test (Roche Molecular Systems).
An important study of the clinical utility of CMV viral load was conducted on liver transplant recipients (3). This study monitored 97 liver transplant recipients for 12 weeks after transplant with weekly quantitative CMV DNA PCR (Amplicor Monitor) testing. High-risk individuals (donor organ CMV seropositive and recipient CMV seronegative) were treated for 12 weeks with ganciclovir and then monitored for an additional 8 weeks. No preemptive therapy was used in the study. Of the 97 individuals enrolled, 61 developed CMV infection, and 21 developed CMV disease. CMV infection was defined as a positive laboratory test (CMV culture, antigenemia, or PCR), whereas CMV disease was defined as end organ involvement with culture or histologic evidence of invasive CMV.
With the use of a positive cutoff of >400 copies/mL of plasma, PCR had a sensitivity of 100%, a specificity of 47%, a positive predictive value of 34%, and a negative predictive value of 100%. Different viral load cutoffs were analyzed using ROC curves. As the viral load cutoff increased, the specificity increased, but the sensitivity decreased. The optimal viral load cutoff predicting disease was 2000-5000 copies/mL of plasma (for >2000 copies/mL, sensitivity, 91%; specificity, 75%; positive predictive value, 50%; negative predictive value, 99.6%) (3).
A similar study was conducted with 52 renal transplant recipients using the hybrid capture assay (4). The risk of CMV disease after renal transplant increased from 1.5% with a viral load of [10.sup.4] copies/mL to 73% with a viral load of [10.sup.6] copies/mL. Notably, the viral load values between the Amplicor and hybrid capture assays did not correlate. The molecular methods are different and the Amplicor assay measured viral load in plasma, whereas the hybrid capture assay measured viral load in whole blood.
Sia et al. (5) evaluated the use of viral load in predicting relapsing CMV infection. Solid organ transplant recipients (n = 24) with CMV infections were treated with ganciclovir for 2 weeks. CMV viral load was measured before and after therapy. Eight of the 24 individuals developed relapsing infection. Persistently detectable viral load after 2 weeks of therapy was associated with relapsing CMV infection (5). Moreover, in a separate study, patients with documented ganciclovir resistance had persistently increased CMV viral load concentrations during therapy (20 000-70 000 copies/mL by the Amplicor assay) (6).
On the basis of the studies described above, it is possible to use a testing protocol to monitor solid organ transplant recipients for the development of CMV disease. Monitoring patients weekly after transplant with a quantitative CMV assay can be used to guide preemptive therapy for CMV infection. When preemptive therapy should be initiated will depend on the assay used, as well as the type of organ transplant. In addition, monitoring viral load after completion of therapy may be useful in predicting relapsing disease.
Improving Overall Disease Management
HIV-1 GENOTYPING TO GUIDE ANTIRETROVIRAL THERAPY
Viral load testing has revolutionized the management of antiretroviral therapy in individuals with HIV-1 infection. Viral load concentrations are used to determine when to initiate antiretroviral therapy, and they are used to monitor patient response to antiretroviral therapy (7). The current standard of care is to treat individuals with combinations of antiretroviral agents and to monitor viral load during therapy. A baseline viral load is obtained before initiating therapy. Viral load is routinely measured 1 month after initiating or changing therapy; it is then monitored monthly until the goal of therapy is reached and every 3 to 4 months thereafter. Testing is performed more frequently if there is a clinical indication (7). The goal is an undetectable viral load, which, depending on the assay, would be <400 copies/mL of plasma or <50 copies/mL of plasma. Failure of antiretroviral therapy refers to the inability to achieve or maintain viral suppression. Causes of treatment failure include development of resistance, nonadherence, and inadequate drug concentrations (8).
HIV-resistance testing can be useful in managing individuals for whom antiretroviral therapy has failed. Several studies evaluating the clinical utility of genotypic testing are reviewed below; however, a summary of studies evaluating phenotypic testing is beyond the scope of this discussion. Methods for genotypic testing include automated sequencing, DNA chip-hybridization assays, and the line-probe assay. Currently, most HIV-1 genotyping for clinical use is performed by the use of automated sequencing methods. The protease gene and the majority of the RT gene are sequenced to identify resistance mutations.
Several trials have established the clinical utility of genotypic assays in the management of individuals with HIV-1 infection (9,10). The VIRADAPT study was a prospective, open, randomized, and controlled study of individuals with HIV-1 infection for whom combination therapy failed (9). Subsequent antiretroviral therapy was managed either by standard of care (control group; n = 43) or on the basis of genotyping results (genotype group; n = 65). At 3 and 6 months after enrollment, the genotype group had a greater decrease in viral load than the control group. The decrease in viral load at 6 months was 1.15 [log.sub.10] for the genotype group vs 0.67 [log.sub.10] for the control group. In addition, at 6 months, 32% of individuals in the genotype group had viral load concentrations <200 copies/mL, whereas 14% of the control group had viral load concentrations <200 copies/mL. After 6 months, individuals in the control arm were offered open-labeled genotypic assays. A benefit was observed in the control group, for which the percentage of individuals achieving an undetectable viral load (<200 copies/mL) increased from 14% at 6 months to 25.7% at 12 months. In addition, the benefit observed in the genotype arm persisted at 12 months (11).
A second prospective randomized controlled trial of antiretrorviral management on the basis of genotyping was conducted with patients for whom therapy had failed (10). Individuals with a threefold or greater increase in viral load after at least 16 weeks of combination antiretroviral therapy were randomized to either the experimental group [genotypic antiretroviral-resistance testing (GART); n = 78], or the control, non-GART group (No-GART; n = 75) group. In the GART group, genotyping was performed and interpretations of the results and suggested regimens were provided to clinicians. In the No-GART group, treatment choices were made without genotyping information. For the GART group, the mean viral load at 4 and 8 weeks after enrollment decreased by 1.19 [log.sub.10]. The No-GART group had decreases in viral load of 0.61 [log.sub.10] during the same time period (P = 0.0001) (10). The best virologic responses occurred in patients who received three or more drugs to which their HIV-1 appeared susceptible. In the study, patients for whom triple-drug therapy had failed responded better when their subsequent regimen was chosen on the basis of genotyping with expert advice compared with those without genotyping (10).
A testing protocol for monitoring individuals with HIV-1 infection during therapy would begin with monitoring viral load. Once there is evidence of virologic failure, there are studies supporting the use of resistance testing in selecting an alternative regimen (9, 10). An international AIDS Society-USA Panel has made recommendations for the use of antiretroviral drug resistance testing in adults with HIV-1 infection on the basis of available data and expert opinion (12). The panel has recommended resistance testing to aid in choosing a regimen for individuals with virologic failure on an initial regimen or to help guide management after numerous regimens have failed. Plasma specimens for resistance testing should be collected during the individual's therapy to maintain drug-selective pressure (12).
Directing Therapy by Virologic Testing
GENOTYPING FOR HEPATITIS C VIRUS (HCV) TO DETERMINE DURATION OF THERAPY
HCV infection is estimated to affect almost 4 million people in the United States (13), and 15-20% will eventually develop cirrhosis (14-16). In North America, Europe, and Australia, chronic HCV infection is the most common indication for liver transplantation (13,17).
HCV is a virus with marked nucleic acid sequence heterogeneity. There are six major genotypes and numerous subtypes. The geographic distribution of the genotypes varies; in North American, genotype 1 predominates (18). There are several methods available for performing HCV genotyping, including DNA sequencing, restriction fragment length polymorphism, cleavase fragment-length polymorphism, and the line-probe assay. HCV genotyping is routinely performed in clinical and reference laboratories using these methods, although sequencing and the line-probe assay are the most commonly used methods at this time.
Two recent multicenter randomized trials have shown that combination therapy with interferon a-2b (IFN) plus ribavirin is effective in the treatment of individuals with chronic HCV infection (19, 20). Several predictors of sustained response have been identified, including viral genotype, low viral load, female gender, lack of fibrosis, and an age <40 years (20). Poynard et al. (20) found genotypes 2 or 3 to be an independent predictor of sustained response, and a stronger predictor of sustained response than baseline viral load. For patients with genotype 2 or 3, there was no improvement in the response rate for those receiving 48 weeks of IFN--ribavirin (64% response rate) compared with 24 weeks of therapy (64% response rate). However, for patients with genotype 1, the likelihood of a sustained response increased from 18% after 24 weeks of therapy to 31% with 48 weeks of therapy. Similar results were observed by McHutchison et al. (19), who found that among patients with HCV genotype 1 infection, the best response rate was observed for those patients treated for 48 weeks with IFN--ribavirin. There was no difference in the response rate between 24 and 48 weeks of therapy in patients with non-1 genotype.
The above studies support the clinical utility of performing genotyping to assist in determining the duration of IFN-ribavirin therapy in patients with chronic HCV infection. Patients with genotype 2 or 3 may receive 24 weeks of therapy, whereas those with genotype 1 usually benefit from 48 weeks of therapy.
In summary, there is clinical utility for the diagnosis and management of CMV, HIV, and HCV by molecular methods. Quantitative PCR determination of CMV viral load in solid organ transplant recipients can predict CMV disease and relapse. Viral load testing in patients with HIV infection is currently used to monitor the efficacy of treatment. Additionally, studies have shown the benefit of using genotyppc assessment to manage antiretroviral therapy. Furthermore, there is evidence that HCV genotyping is useful for determining the duration of IFN--ribavirin therapy. These three examples demonstrate the clinical utility of molecular testing protocols in virology.
Received February 2, 2001; accepted May 11, 2001.
(1.) Crumpacker CS. Cytomegalovirus. Philadelphia: Churchill Livingstone, 2000:1586-99.
(2.) Griffiths PD, Emory VC. Cytomegalovirus. New York: Churchill Livingstone, 1997:445-70.
(3.) Humar A, Gregson D, Caliendo AM, McGeer A, Malkan G, Krajden M, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in livertransplant recipients. Transplantation 1999;68:1305-11.
(4.) Aitken C, Barrett-Muir W, Millar C, Templeton K, Thomas J, Sheridan F, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999;37:2804-7.
(5.) Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000;181:717-20.
(6.) Caliendo AM, St. George K, Kao S-Y, Allega J, Tan B-H, LaFontaine R, Bui L, Rinaldo CR. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000;38:2122-7.
(7.) Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel [see comments]. JAMA 2000;283:381-90.
(8.) Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel [see comments]. JAMA 1998;279:1984-91.
(9.) Durant J, Clevenberg P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotypying in HIV-1 therapy: the VARADAPT randomised controlled trial. Lancet 1999;353: 2195-9.
(10.) Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotyppc antiretroviral resistance testing in patients failing therapy. AIDS 1999;14:F83-93.
(11.) Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro JM, Boucher CA, Dellamonica P. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antivir Ther 2000;5:65-70.
(12.) Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA panel. JAMA 2000;283:2417-26.
(13.) National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26(Suppl 1):2S-10S.
(14.) Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(Suppl 1):62S-5S.
(15.) Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
(16.) Tong MJ, EI-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332: 1463-6.
(17.) Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219-28.
(18.) Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:218-89.
(19.) McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Group ftHIT interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
(20.) Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alb plus ribavirin for 48 weeks or for 24 weeks versus interferon alb plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
 Nonstandard abbreviations: CMV, cytomegalovirus; HCV, hepatitis C virus; IFN, [alpha]-2b interferon; CART, genotypic antiretroviral-resistance testing; No-GART, non-CART; and HCV, hepatitis C virus.
VIOLET A. KELLEY AND ANGELA M. CALIENDO *
Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA 30322.
* Address correspondence to this author at: Clinical Laboratory, Emory University Hospital, F147, 1364 Clifton Road, Atlanta, GA 30322. Fax 404-712-4632; e-mail firstname.lastname@example.org.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Beckman Conference|
|Author:||Kelley, Violet A.; Caliendo, Angela M.|
|Date:||Aug 1, 2001|
|Previous Article:||Molecular detection of mycobacterium tuberculosis: impact on patient care.|
|Next Article:||Guidelines and algorithms: perceptions of why and when they are successful and how to improve them.|